分析师调整了BioLineRx和BioNTEch的收益估计数,对两者都保持了“Buy”评级。 Analysts adjusted earnings estimates for BioLineRx and BioNTech, maintaining a "Buy" rating for both.

HC Wainwright将生物技术公司BioLineRx的2025年Q3收入估计数提高到每股0.41美元, HC Wainwright raised its Q3 2025 earnings estimates for BioLineRx, a biotech company, to ($0.41) per share from ($0.43), maintaining a "Buy" rating. 与此同时,Zacks Research将2025年Biogen的Q3收入估计数从3.85美元降至3.81美元,尽管Biogen最近报告了5.47 EPS,殴打估计数。 Meanwhile, Zacks Research lowered Biogen's Q3 2025 earnings estimates to $3.81 from $3.85, though Biogen recently reported $5.47 EPS, beating estimates. HC Wainwright也将其2025年BioNTECH的EPS估计量降低到(1.61), HC Wainwright also lowered its Q3 2025 EPS estimates for BioNTech to ($1.61) from ($1.12), with a "Buy" rating.